Insigniam Partner Jon Kleinman Appointed as Advisor to The APANDEMIC Initiative To Combat Patient Deaths From COVID-19

Share Article

Jon Kleinman, a partner at the international management consulting firm, Insigniam, was recently appointed to serve on the advisory board of the APANDEMIC Initiative. He will serve among the group of physicians, medical researchers, therapy developers, data scientists, engineers, and organizational leaders who have joined forces to help end the COVID-19 crisis.

“I am honored to be a part of this incredibly important initiative,” said Mr. Kleinman. “Insigniam exists to serve, and I look forward to being of service to this incredible group of dedicated, passionate professionals who have come together in a shared commitment to the health of all human beings."

Jon Kleinman, a partner at the international management consulting firm, Insigniam, was recently appointed to serve on the advisory board of the APANDEMIC Initiative. He will serve among the group of physicians, medical researchers, therapy developers, data scientists, engineers, and organizational leaders who have joined forces to help end the COVID-19 crisis.

“I am honored to be a part of this incredibly important initiative,” said Mr. Kleinman. “Insigniam exists to serve, and I look forward to being of service to this incredible group of dedicated, passionate professionals who have come together in a shared commitment to the health of all human beings."

The APANDEMIC Initiative’s purpose is to deliver access to promising investigational therapies to all patients whose lives are threatened by COVID-19. The organization formed based on a vision to radically transform and accelerate the development, approval, and access to new therapies. As an advisor, Jon brings over two decades of experience in organizational transformation, innovation and breakthrough thinking to the group.

The APANDEMIC Initiative states of their intention, “In our approach, patients are offered immediate and broad access to promising investigational therapies. Importantly, their clinical outcomes are tracked and evaluated in real-time, using 21st-century science, methods, and digital technology. This can be achieved through a Real-World Evidence Master Protocol on an Integrated Research Platform (RWE-IRP).”

About Insigniam
For over 30 years, Insigniam has consulted with large, complex organizations in generating breakthroughs in strategic results: top-line growth, strategy implementation, improving profitability, strategic innovation, and cultural transformation. Insigniam pioneered the fields of organizational transformation and strategy innovation by marrying breakthrough performance and innovation, creating services and solutions that are unparalleled in their potency to quickly create dramatic growth and market leadership. Clients have documented, in aggregate, more than 50x ROI in results considered critical and essential to the success of their enterprises. Offices are located in Southern California, Paris, and Philadelphia.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Natalie Rahn
Insigniam
+1 610-667-7822
Email >
Visit website